labscreen covid plus assay  (Thermo Fisher)

Journal: Open Forum Infectious Diseases

Article Title: Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 and Other Coronaviruses, December 2019 to July 2020

doi: 10.1093/ofid/ofae351

Figure Lengend Snippet: A , Study testing algorithm and sample flow. Donation samples (n = 46 120) were tested using the Roche Elecsys Anti-SARS-CoV-2 electrochemiluminescence assay (ECLIA) detecting nucleocapsid (N) and total immunoglobulins (Total Ig). The 92 anti-N­–reactive samples (referred to as presumptive positives ) with adequate volume (n = 91) were tested using the semiquantitative Elecsys Anti-SARS-CoV-2 S immunoglobulin G (IgG) ECLIA, a research semiquantitative anti–severe acute respiratory syndrome coronavirus (SARS-CoV-2) receptor-binding domain (RBD) IgG assay, and the One Lambda LABScreen COVID Plus IgG assay. The 55 RBD reactive samples were considered confirmed positive and were further tested using a research pseudoneutralization assay, the blockade of angiotensin-converting enzyme 2 binding (BoAB) assay (directed to the Wuhan strain). The 91 presumptive positives with adequate volume were further investigated using the Ortho VITROS Anti-SARS-CoV-2 Total Ig N and VITROS Anti-SARS-CoV-2 Total Ig S chemiluminescent immunoassays (ChLIAs), noted by dashed lines in the testing flow. Of the Elecsys anti-N ECLIA–reactive samples, 1 had insufficent volume for further testing (QNS) after initial screening, 11 were QNS with the VITROS Anti-SARS-CoV-2 Total Ig N assay, and 29 were QNS with the VITROS Anti-SARS-CoV-2 Total Ig S ChLIA. B, Results of antibody testing of 91 presumptive-positive samples with further anti–SARS-CoV-2 assays. Each of the 91 Elecsys anti-N ECLIA reactive samples was tested using Elecsys anti-S ECLIA and research anti-RBD assays as well as the LABScreen COVID Plus assay, as shown in A . Reactivity to the anti-S and anti-RBD assays established criteria (manufacturer's insert or internal validation) for the cutoff, with reactivity read as units per milliliter, whereas response to any of the 5 anti–SARS-CoV-2 targets of the LABScreen assay was defined as reactive if above the manufacturer's established cutoff. Of the 91 total anti-N-ECLIA reactive samples, 29 (31.9%) were anti-S ECLIA reactive in combination with other markers, 55 (60.4%) anti-RBD reactive alone or in combination with other markers, and 37 (40.7%) LABScreen assay reactive alone or in combination with other markers; 28 (30.8%) were reactive by all 3 assays (anti-S ECLIA, anti-RBD and LABScreen). Dual-marker reactivity included 1 (1.1%) by anti-S and anti-RBD assay and 4 (4.4%) by anti-RBD and LABScreen assay. Single-marker reactivity included 22 (24.2%) by anti-RBD assay only and 5 (5.5%) by LABScreen assay only.

Article Snippet: Presumptive-positive samples were tested on the LABScreen COVID Plus assay (One Lambda; www.onelambda.com ) at the ARC Histocompatibility Laboratory Services.

Techniques: Electrochemiluminescence, Binding Assay, Marker

Journal: Open Forum Infectious Diseases

Article Title: Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 and Other Coronaviruses, December 2019 to July 2020

doi: 10.1093/ofid/ofae351

Figure Lengend Snippet: Reactivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed-positive samples over time. Reactivity over time where all 3 panels ( A, B, and C ) show an upward trend in raw values/percentage reactivity for the 55 confirmed-positive samples (collected from 13 December 2019 to 5 July 2020) correlating with the start of the pandemic in the United States. A , Values for samples over time with each assay represented by a separate line: Elecsys Anti-SARS-CoV-2 N (nucleocapsid) electrochemiluminescence assay (ECLIA) (reactivity based on cutoff index), Elecsys Anti-SARS-CoV-2 S (spike) ECLIA (reactivity measured in units per milliliter) and anti–SARS-CoV-2 receptor-binding domain (RBD) (units per milliliter). All samples were reactive for anti-N and anti-RBD; anti-S­–tested samples with >0.80 U/mL were considered reactive. Reactivity by assay was compared for samples collected over 2 periods of time: 13 December 2019 to 22 March 2020 versus 23 March to 5 July 2020; for each assay (anti-N, anti-RBD, and anti-S), reactivity in the latter period was significantly higher ( P < .001). B , Percentage reactivity over time for the anti-S (units per milliliter) and the blockade of angiotensin-converting enzyme 2 binding (BoAB; neutralization percentage for either Wuhan or Delta variant) assays. C , Percentage reactivity over time for each of the 5 SARS-CoV-2 analytes of the LABScreen COVID Plus assay; each line indicates an individual analyte. Abbreviations: S1, S subunit 1; S2, S subunit 2.

Article Snippet: Presumptive-positive samples were tested on the LABScreen COVID Plus assay (One Lambda; www.onelambda.com ) at the ARC Histocompatibility Laboratory Services.

Techniques: Electrochemiluminescence, Binding Assay, Neutralization, Variant Assay

Journal: Open Forum Infectious Diseases

Article Title: Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 and Other Coronaviruses, December 2019 to July 2020

doi: 10.1093/ofid/ofae351

Figure Lengend Snippet: Evaluation of the presence of antibodies against other coronaviruses. The presence of antibodies against the 4 common cold coronaviruses (human coronavirus [HCoV] 229E, HCoV HKU1, HCoV NL63, and HCoV OC43), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), for the 55 SARS coronavirus 2 (SARS-CoV-2) confirmed-positive samples was assessed with the LABScreen COVID Plus IgG assay. A , Box plots of the LABScreen COVID Plus assay showing the fluorescence intensity for the 4 common cold coronaviruses, MERS-CoV, and SARS-CoV. All 55 samples showed some to minimal reactivity to the spike (S) subunit 1 (S1) of the 4 common cold coronaviruses but showed virtually no reactivity to S1 of MERS-CoV or SARS-CoV. , Fluorescence intensities for the 55 SARS-CoV-2 confirmed-positive samples to each common cold coronavirus, MERS-CoV, and SARS-CoV by the collection date. The S reactivity for each cold coronavirus was compared for samples collected over 2 periods of time: 13 December 2019 to 22 March 2020 versus 23 March to 5 July 2020. No significant trends in fluorescence intensities were observed over time for any of these viruses; MERS-CoV and SARS-CoV were excluded since minimal or no reactivity was observed. C , Fluorescence intensities of the 55 SARS-CoV-2 confirmed-positive samples to each LABScreen COVID Plus SARS-CoV-2 analyte show the identical trends observed in . That is, reactivity by assay were compared for samples collected over 2 periods: 13 December 2019 to 22 March 2020 versus 23 March to 5 July 2020; for each assay (anti-S, S1, and subunit 2 [S2], nucleocapsid [N] and receptor-binding domain [RBD]), the latter time period had significantly higher reactivity ( P < .001).

Article Snippet: Presumptive-positive samples were tested on the LABScreen COVID Plus assay (One Lambda; www.onelambda.com ) at the ARC Histocompatibility Laboratory Services.

Techniques: Fluorescence, Binding Assay

Journal: Frontiers in Immunology

Article Title: Comprehensive assessment of SARS-CoV-2 antibodies against various antigenic epitopes after naive COVID-19 infection and vaccination (BNT162b2 or ChAdOx1 nCoV-19)

doi: 10.3389/fimmu.2022.1038712

Figure Lengend Snippet: Kinetics of antibody response by multiplex (One-lambda), Roche and GenScript assay in naïve COVID-19 infection (n=32) (A) , AZ/AZ vaccination (n=20) (B) and BNT/BNT (n=20) vaccination (C) . X-axis shows the time point presented in days after symptom onset (A) and in weeks after the 1st-dose vaccination (B, C) . The 1st- and 2nd-dose vaccination time points are indicated by dotted lines. Data are presented as median and IQR.

Article Snippet: LABScreen™ COVID Plus Assay (One Lambda Inc., West Hills, CA, USA) is a multiplex semi-quantitative assay that detects antibodies against five SARS-CoV-2 targets: full S, S1, S2, RBD and N. For informational purposes, the panel also includes additional targets for seasonal coronaviruses, SARS, and MERS, namely HCoV-229E, HCoV-HKU1, HCoV-NL63, HCoV-OC43, MERS-CoV, and SARS-CoV.

Techniques: Multiplex Assay, Infection

Journal: Immunology Letters

Article Title: SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4 + T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer

doi: 10.1016/j.imlet.2022.09.007

Figure Lengend Snippet: Frequency of SARS-CoV-2 M, N, S, S1 protein-reactive T cells detected in PBMCs of convalescent COVID-19 patients and healthy individuals. Frequency of IFN-γ, IL-2 and TNF-α expressing CD4 + or CD8 + T cells detected after stimulation with respective SARS-CoV-2 M, N and S/S peptide mixes among T cells from convalescent COVID-19 patients and HI. Each closed black circles represent a single measurement of one convalescent COVID-19 patients. Each grey triangle represent a single measurement of one HIs. Symbols and bars represent median and range. Statistically significant differences (p<0.05) between groups of antigen-reactive T cells are indicated with horizontal bars and *. Highly statistical differences (p<0.01) are indicated with horizontal bars and **.

Article Snippet: In order to extend the characterization of the humoral response to additional SARS-CoV-2 antigens including the RBD, nucleocapsid (N), S1/S2 domain and to the S1 domain of various relevant HCoVs (HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-NL63) the serum of reconvalescent COVID-19 patients was further assessed using the SARS-CoV-2 specific multiplex antibody detection array (MABA) (Labscreen COVID plus) (One lambda, West Hill, CA, USA) and HLA Fusion software (Luminex, Austin, TX, USA)).

Techniques: Expressing

Journal: Immunology Letters

Article Title: SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4 + T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer

doi: 10.1016/j.imlet.2022.09.007

Figure Lengend Snippet: Generation and maintenance of SARS-CoV-2-reactive IFN-γ + CD4 + T cells in con-valescent patients up to 256 days after onset of disease. Frequency of SARS-CoV-2-N or S peptide mix-reactive IFN-γ + CD4 + T cells in convalescent patients up to 256 days after onset of disease, respectively ( a and b). Regression lines, coefficient of variations (r 2 ) and statistical significance (p-value) are depicted in the Figures. Each symbol represents a single measurement.

Article Snippet: In order to extend the characterization of the humoral response to additional SARS-CoV-2 antigens including the RBD, nucleocapsid (N), S1/S2 domain and to the S1 domain of various relevant HCoVs (HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-NL63) the serum of reconvalescent COVID-19 patients was further assessed using the SARS-CoV-2 specific multiplex antibody detection array (MABA) (Labscreen COVID plus) (One lambda, West Hill, CA, USA) and HLA Fusion software (Luminex, Austin, TX, USA)).

Techniques:

Journal: Immunology Letters

Article Title: SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4 + T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer

doi: 10.1016/j.imlet.2022.09.007

Figure Lengend Snippet: Correlation of anti-HCoV-NL63 S1/anti-HCoV-229E S1 protein-specific IgGs levels with anti-SARS-CoV-2 S/S1-specific IgGs levels and SARS-CoV-2 neutralizing antibody titer. MFI values of anti-SARS-CoV-2 S1-specific IgGs levels determined by MABA were compared with MFI values of anti-HCoV-NL63 S1-protein-specific IgGs ( a) or anti-HCoV-2-229E S1-protein-specific IgGs ( b) also determined by MABA in sera of convalescent COVID-19 patients. The titer of SARS-CoV-2 neutralizing antibodies is correlated to MFI values of anti-HCoV-NL63 S1-protein-specific IgGs ( c). Regression lines, coefficient of variations (r 2 ) and statistical significance (p-value) are depicted in the Figures. Each symbol represents a single measurement.

Article Snippet: In order to extend the characterization of the humoral response to additional SARS-CoV-2 antigens including the RBD, nucleocapsid (N), S1/S2 domain and to the S1 domain of various relevant HCoVs (HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-NL63) the serum of reconvalescent COVID-19 patients was further assessed using the SARS-CoV-2 specific multiplex antibody detection array (MABA) (Labscreen COVID plus) (One lambda, West Hill, CA, USA) and HLA Fusion software (Luminex, Austin, TX, USA)).

Techniques:

Journal: Immunology Letters

Article Title: SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4 + T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer

doi: 10.1016/j.imlet.2022.09.007

Figure Lengend Snippet: Correlation of SARS-CoV-2 neutralizing antibody titer with the frequency of anti-SARS-CoV-2 S1 protein-reactive INF-γ + CD4 + T cells detected in convalescent COVID-19 patients. Titer of SARS-CoV-2 neutralizing antibodies were compared with the frequency of anti-SARS-CoV-2 S1 protein-reactive INF-γ + CD4 + T cells detected in convalescent COVID-19 patients. Regression lines, coefficient of variations (r 2 ) and statistical significance (p-value) are depicted in the Figure. Each symbol represents a single measurement.

Article Snippet: In order to extend the characterization of the humoral response to additional SARS-CoV-2 antigens including the RBD, nucleocapsid (N), S1/S2 domain and to the S1 domain of various relevant HCoVs (HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-NL63) the serum of reconvalescent COVID-19 patients was further assessed using the SARS-CoV-2 specific multiplex antibody detection array (MABA) (Labscreen COVID plus) (One lambda, West Hill, CA, USA) and HLA Fusion software (Luminex, Austin, TX, USA)).

Techniques: